ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative2.2 B2.08 B2.14 B2.16 B2.35 B8.73 BRicerca e sviluppo374 M342 M352 M346 M357 M1.4 BReddito operativo2.02 B1.72 B1.83 B1.94 B2.25 B7.75 BProventi non operativi, Totale255 M208 M275 M240 M271 M994 MOneri finanziari, al netto degli interessi capitalizzati317 M303 M404 M347 M365 M1.42 BProventi non operativi, esclusi gli oneri finanziari-75 M-98 M-110 M-105 M-100 M-413 MEntrate/uscite straordinarie13 M3 M-19 M-2 M6 M-12 MUtile al lordo delle imposte1.97 B1.61 B1.71 B1.83 B2.12 B7.27 BQuota di utile33 M-14 M2 M2 M-31 M-41 MImposte149 M95 M92 M207 M153 M547 MInteressi di minoranza-7 M4 M2 M5 M6 M17 MAltri proventi/oneri al netto delle imposte-254 M-135 M-63 M-117 M-140 M-455 MUtile netto al lordo delle attività cessate1.83 B1.51 B1.62 B1.62 B1.96 B6.7 BAttività cessate——————Utile netto1.83 B1.51 B1.62 B1.62 B1.96 B6.7 BRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari1.83 B1.51 B1.62 B1.62 B1.96 B6.7 BUtile base per azione (EPS base)4.83.994.284.285.2217.77Utile diluito per azione (EPS diluito)4.783.984.284.275.2117.74Numero medio di azioni ordinarie in circolazione382 M378 M378 M378 M377 M1.51 BAzioni diluite in circolazione383 M379 M378 M378 M378 M1.51 BEBITDA4.27 B2.42 B2.95 B3.46 B4.28 B13.11 BEBIT2.02 B1.72 B1.83 B1.94 B2.26 B7.75 BCosto del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)2.26 B705 M1.11 B1.52 B2.02 B5.36 B
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain.